How Long Does VEGF Stay in Your System? Half-Life and Clearance Literature

Questions about how long vascular endothelial growth factor (VEGF) "stays in your system" usually collapse three different things into one: the behaviour of the body's own VEGF protein, the behaviour of VEGF-family proteins administered in animal research, and the behaviour of the pharmaceutical agents designed to block VEGF signalling. These have very different pharmacokinetic profiles, and only some of them have been measured in humans. This page separates compound-specific pharmacokinetic literature from general protein pharmacology, and says plainly which is which. For the broader framework, see how long peptides stay in your system; for background on the molecule itself, see VEGF.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing here describes how any substance should be used.

The Short Answer

There is no single published half-life that answers the question for "VEGF" as a category. Endogenous VEGF-A circulates at low concentrations and is continuously produced and consumed, so the useful question in the literature is not when it disappears but how fast tissue turnover and clearance pathways handle it. Where human pharmacokinetic numbers do exist, they belong to engineered molecules: bispecific antibodies, antibody fragments, fusion proteins and oral kinase inhibitors that act on the VEGF pathway. Researchers evaluated the safety, pharmacokinetics and pharmacodynamics of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in Chinese patients with advanced solid tumours (PMID 40114411), and a review of the pharmacokinetics of biologics in gastric cancer summarised how such antibody-based agents behave after systemic administration (PMID 36631818).

What "Half-Life" Actually Measures

Half-life describes the time for the measured concentration of a substance in a defined compartment, usually plasma, to fall by half during the elimination phase. Three distinctions matter when reading VEGF-related pharmacokinetics:

• Distribution versus elimination. Proteins given intravenously often show a rapid early fall as they distribute into tissue and interstitial space, followed by a slower terminal phase.
• Plasma versus compartment. An agent injected into the eye is measured in vitreous and in serum separately, and those curves differ by orders of magnitude in concentration.
• Drug versus effect. Pharmacodynamic consequences, such as suppression of circulating free VEGF or changes in vascular permeability, can outlast measurable drug concentrations.

The review of nintedanib's clinical pharmacokinetics and pharmacodynamics made exactly this separation for an orally administered angiokinase inhibitor acting on VEGF receptors (PMID 31016670).

Compound-Specific Human Pharmacokinetic Literature

Systemically administered VEGF-pathway biologics

Antibody-based agents are the best-characterised group. The study of ivonescimab in patients with advanced solid tumours was designed to characterise safety alongside pharmacokinetics and pharmacodynamics, meaning exposure was measured serially rather than inferred (PMID 40114411). More broadly, the review of biologic pharmacokinetics in gastric cancer described how monoclonal antibodies used in oncology, including agents directed at the VEGF axis, are handled after infusion (PMID 36631818). As general protein pharmacology rather than a finding from any single cited paper: full-length IgG molecules persist for days to weeks because neonatal Fc receptor recycling rescues them from lysosomal degradation, while fragments lacking an Fc region are cleared far faster.

Small-molecule VEGF receptor inhibitors

Oral inhibitors of VEGF receptor kinases are not peptides at all, and their disposition follows small-molecule rules: gastrointestinal absorption, hepatic metabolism, and excretion in bile or urine. The nintedanib review summarised the clinical pharmacokinetics and pharmacodynamics of that agent across its approved settings (PMID 31016670), and a development review of tivozanib described the status of that VEGF receptor inhibitor's clinical programme (PMID 25895472). These agents are relevant to the "how long" question because sustained receptor blockade, not residual VEGF protein, is what prolongs pathway suppression.

Intravitreal agents and compartment pharmacokinetics

The eye is the clearest illustration that "in your system" depends on which system. A review of ranibizumab in retinopathy of prematurity summarised the pharmacology and clinical use of that antibody fragment in preterm infants (PMID 33447937), while a long-term analysis reported outcomes with repeated intravitreal aflibercept injections in diabetic macular oedema (PMID 28427067). Researchers also described a bispecific CrossMAb targeting key angiogenic pathways that was engineered specifically for neovascular eye diseases (PMID 27742718), an example of molecular design being matched to an intended compartment. Clearance out of the eye also depends on the eye's anatomy: a review of the physiology of vitreous surgery described how surgical alteration of the vitreous changes the intraocular environment (PMID 19034481), a reminder that compartment turnover is not a fixed property.

VEGF-family proteins given in animal research

For VEGF-family proteins administered as the agent rather than the target, most available data are preclinical. Researchers reported that VEGF-C prophylaxis favoured lymphatic drainage and modulated neuroinflammation in a mouse stroke model (PMID 38442272). That study characterised biological consequences in tissue rather than publishing a human plasma half-life, which is the pattern across this literature.

How the Body Removes Large Signalling Proteins

The following describes general protein and peptide pharmacology, not a measurement from a specific VEGF trial. Growth factors of this size are not primarily cleared by the liver in the way small molecules are. Instead:

• Receptor-mediated uptake. Binding to VEGF receptors on endothelial cells internalises and degrades the ligand, which makes clearance partly dependent on how much receptor is available, a saturable, non-linear process.
• Proteolysis. Peptidases in plasma and tissue cleave exposed sequences; extracellular matrix binding of certain VEGF isoforms shelters them from this.
• Renal handling. Molecules below roughly the glomerular filtration cut-off are filtered and catabolised in the proximal tubule; larger multimeric proteins are not efficiently filtered.
• Lymphatic transport. Interstitial macromolecules return to the circulation largely through lymph. A review of lymphatic clearance in cardiovascular disease described how lymphatic vessels remove cells and material from tissue (PMID 34685572), and work on cerebrospinal fluid clearance through arachnoid fenestrations to olfactory meningeal lymphatics mapped an anatomical exit route from the central nervous system (PMID 42480526).

Comparison of Exposure Patterns Reported in the Literature

Factors That Change Clearance

Across the cited pharmacokinetic literature, several variables consistently alter exposure:

1. Molecular format. Fc-containing antibodies, Fc-free fragments, fusion proteins and small molecules sit at different ends of the persistence spectrum; the CrossMAb work illustrated deliberate engineering for a target compartment (PMID 27742718).
2. Route and compartment. Intravitreal administration produces high local and low systemic concentrations, as reflected in the long-term aflibercept analysis in diabetic macular oedema (PMID 28427067).
3. Tissue architecture. The review of vitreous surgery physiology described how altering a compartment changes its transport properties (PMID 19034481).
4. Target burden. Receptor- and antigen-mediated clearance is saturable, so disease state and tumour load influence exposure, a theme of the gastric cancer biologics review (PMID 36631818).
5. Organ function and metabolism. For oral inhibitors, hepatic and gastrointestinal handling dominate, as summarised for nintedanib (PMID 31016670).
6. Lymphatic function. Drainage capacity shapes how fast interstitial macromolecules return to blood (PMID 34685572).

Pathway Suppression Outlasting Drug Levels: What Studies Report

Because VEGF-pathway agents act on a vascular signalling system, their biological footprint is not bounded by their measured concentration. A review of anti-VEGF agents and the risk of arteriothrombotic events examined whether systemic cardiovascular events were associated with these therapies (PMID 29405046), which is the clearest reason the "how long until it is gone" framing is incomplete. The study of ivonescimab was explicitly structured to report safety alongside pharmacokinetics and pharmacodynamics in patients with advanced solid tumours (PMID 40114411), reflecting how adverse-event monitoring and exposure measurement are handled together. In animal work, researchers reported that VEGF-C prophylaxis modulated neuroinflammation as well as lymphatic drainage in a stroke model (PMID 38442272), a downstream effect on tissue biology rather than a concentration measurement.

Limits of the Evidence

Three limits are worth stating directly. First, human pharmacokinetic data in this field describe approved or investigational pharmaceuticals, not research-grade VEGF protein, and the ivonescimab study enrolled patients with advanced solid tumours rather than healthy volunteers (PMID 40114411). Second, findings from a mouse stroke model do not transfer directly to human timelines (PMID 38442272). Third, clearance-anatomy research continues to revise basic assumptions, the mapping of cerebrospinal fluid clearance through arachnoid fenestrations to olfactory meningeal lymphatics is a recent example of a route being characterised after decades of study (PMID 42480526).

Related Reading

• How Long Do Peptides Stay in Your System?
• VEGF: overview of the literature

References

• Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors (Cancer Medicine, 2025)
• Pharmacokinetics of biologics in gastric cancer (Clinical and Translational Science, 2023)
• Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib (Clinical Pharmacokinetics, 2019)
• Tivozanib: status of development (Current Oncology Reports, 2015)
• Ranibizumab: A Review in Retinopathy of Prematurity (Paediatric Drugs, 2021)
• Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes (Developments in Ophthalmology, 2017)
• Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases (EMBO Molecular Medicine, 2016)
• Physiology of vitreous surgery (Graefe's Archive for Clinical and Experimental Ophthalmology, 2009)
• VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model (Journal of Experimental Medicine, 2024)
• Lymphatic Clearance of Immune Cells in Cardiovascular Disease (Cells, 2021)
• CSF clearance through arachnoid fenestrations to olfactory meningeal lymphatics (Cell, 2026)
• Anti-VEGF Agents and the Risk of Arteriothrombotic Events (Asia-Pacific Journal of Ophthalmology, 2018)